Literature DB >> 9799593

The molecular basis of disease variability among cystic fibrosis patients carrying the 3849+10 kb C-->T mutation.

O Chiba-Falek1, E Kerem, T Shoshani, M Aviram, A Augarten, L Bentur, A Tal, E Tullis, A Rahat, B Kerem.   

Abstract

Disease severity varies among cystic fibrosis (CF) patients carrying the same CFTR genotype. Here we studied the mechanism underlying disease variability in individuals carrying a splicing CFTR mutation, 3849+10 kb C-->T. This mutation was shown to produce both correctly and aberrantly spliced CFTR transcripts containing an additional cryptic exon. Semiquantitative nondifferential RT-PCR showed considerable variability in the level (0-28%) of aberrantly spliced RNA transcribed from the 3849+10 kb C-->T mutation in nasal epithelium from 10 patients. A significant inverse correlation was found between the level of the aberrantly spliced CFTR transcripts and pulmonary function, expressed as FEV1 (r = 0.92, P < 0.0001). Patients with normal pulmonary function (FEV1 > 80% predicted) had lower levels of aberrantly spliced CFTR RNA (0 to 3%) than those with FEV1 < 80%, (9 to 28% aberrantly spliced RNA). Only aberrantly spliced CFTR RNA was detected in the lung of a patient with severe lung disease who underwent lung transplantation. Our results show that the severity of CF lung disease correlates with insufficiency of normal CFTR RNA. Thus, the regulation of alternative splice site selection may be an important mechanism underlying partial penetrance in CF. Further understanding of this regulation will contribute to potential therapy for patients carrying splicing mutations in human disease genes. Copyright 1998 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9799593     DOI: 10.1006/geno.1998.5517

Source DB:  PubMed          Journal:  Genomics        ISSN: 0888-7543            Impact factor:   5.736


  24 in total

1.  Assessing the residual CFTR gene expression in human nasal epithelium cells bearing CFTR splicing mutations causing cystic fibrosis.

Authors:  Laia Masvidal; Susana Igreja; Maria D Ramos; Antoni Alvarez; Javier de Gracia; Anabela Ramalho; Margarida D Amaral; Sara Larriba; Teresa Casals
Journal:  Eur J Hum Genet       Date:  2013-10-16       Impact factor: 4.246

2.  In vivo and in vitro ivacaftor response in cystic fibrosis patients with residual CFTR function: N-of-1 studies.

Authors:  Meghan E McGarry; Beate Illek; Ngoc P Ly; Lorna Zlock; Sabrina Olshansky; Courtney Moreno; Walter E Finkbeiner; Dennis W Nielson
Journal:  Pediatr Pulmonol       Date:  2017-01-09

3.  Constitutional high expression of an APC mRNA isoform in a subset of attenuated familial adenomatous polyposis patients.

Authors:  Tiziana Venesio; Antonella Balsamo; Christian Sfiligoi; Luca Fuso; Sara Molatore; Guglielmina Nadia Ranzani; Mauro Risio
Journal:  J Mol Med (Berl)       Date:  2006-12-02       Impact factor: 4.599

4.  Incomplete cryptic splicing by an intronic mutation of OCRL in patients with partial phenotypes of Lowe syndrome.

Authors:  Eiji Nakano; Amine Yoshida; Yudai Miyama; Tomoo Yabuuchi; Yuko Kajiho; Shoichiro Kanda; Kenichiro Miura; Akira Oka; Yutaka Harita
Journal:  J Hum Genet       Date:  2020-05-19       Impact factor: 3.172

Review 5.  The roles of RNA processing in translating genotype to phenotype.

Authors:  Kassie S Manning; Thomas A Cooper
Journal:  Nat Rev Mol Cell Biol       Date:  2016-11-16       Impact factor: 94.444

Review 6.  Emerging technologies for cystic fibrosis transmembrane conductance regulator restoration in all people with CF.

Authors:  Marie E Egan
Journal:  Pediatr Pulmonol       Date:  2021-02

Review 7.  Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice.

Authors:  C Castellani; H Cuppens; M Macek; J J Cassiman; E Kerem; P Durie; E Tullis; B M Assael; C Bombieri; A Brown; T Casals; M Claustres; G R Cutting; E Dequeker; J Dodge; I Doull; P Farrell; C Ferec; E Girodon; M Johannesson; B Kerem; M Knowles; A Munck; P F Pignatti; D Radojkovic; P Rizzotti; M Schwarz; M Stuhrmann; M Tzetis; J Zielenski; J S Elborn
Journal:  J Cyst Fibros       Date:  2008-05       Impact factor: 5.482

8.  Intragenic modifiers of hereditary spastic paraplegia due to spastin gene mutations.

Authors:  Ingrid K Svenson; Mark T Kloos; P Craig Gaskell; Martha A Nance; James Y Garbern; Shin-ichi Hisanaga; Margaret A Pericak-Vance; Allison E Ashley-Koch; Douglas A Marchuk
Journal:  Neurogenetics       Date:  2004-07-10       Impact factor: 2.660

Review 9.  [Molecular genetics principles in cystic fibrosis. An example of genetic illness in pneumology].

Authors:  B Tümmler; M Stuhrmann
Journal:  Internist (Berl)       Date:  2003-06       Impact factor: 0.743

10.  Traveling stripes on the skin of a mutant mouse.

Authors:  Noboru Suzuki; Masashi Hirata; Shigeru Kondo
Journal:  Proc Natl Acad Sci U S A       Date:  2003-07-31       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.